Bexarotene

Generic Name: Bexarotene

Brand Names: Targretin

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₈O_₂

CAS Number: 153559-49-0

Unique Ingredient Identifier: A61RXM4375

Background: Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.

Indication: 用于全身治疗无效的皮肤Ｔ细胞淋巴癌（CTCL）。

Associated Conditions: Refractory Cutaneous T-cell Lymphoma

Associated Therapies: -

Clinical Trials

Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: bexarotene
Drug: gemcitabine hydrochloride

First Posted Date: 2008-04-17

Last Posted Date: 2014-12-03

Lead Sponsor: University College, London

Target Recruit Count: 36

Registration Number: NCT00660231

Locations: 🇬🇧
Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom
🇬🇧
St. Thomas' Hospital, London, England, United Kingdom
🇬🇧
Royal Cornwall Hospital, Truro, England, United Kingdom

and more 4 locations

Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia

Phase 2

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Bexarotene

First Posted Date: 2008-02-14

Last Posted Date: 2020-12-17

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 24

Registration Number: NCT00615784

Locations: 🇺🇸
Abramson Cancer Center of University of Pennsylvania, Philadelphia, Pennsylvania, United States

Bexarotene Augmentation of Antipsychotic Treatment for Chronic Schizophrenia

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: Bexarotene (Targretin LGD1069)
Drug: bexarotene

First Posted Date: 2007-09-26

Last Posted Date: 2012-07-26

Lead Sponsor: Beersheva Mental Health Center

Target Recruit Count: 90

Registration Number: NCT00535574

Locations: 🇮🇱
Sha'ar Menashe Mental Health Center,, Hadera,, Israel
🇮🇱
Abarbanel Mental Health Center, Bat-Yam, Israel
🇮🇱
Be'er Sheva Mental Health Center, Be'er Sheva,, Be'er Sheva, Israel

Bexarotene and Fenretinide as Addition to Antipsychotic Treatment in Schizophrenia Patients

Phase 3

Withdrawn

Conditions: Schizoaffective Disorder
Cognition
Schizophrenia

First Posted Date: 2007-09-26

Last Posted Date: 2010-06-29

Lead Sponsor: Beersheva Mental Health Center

Registration Number: NCT00534898

Locations: 🇮🇱
Be'er Sheva Mental Health Center, Sha'ar Menashe Mental Health Center, Be'er Sheva, Hadera, Israel

Bexarotene, Tretinoin, and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2

Conditions: Lung Cancer

First Posted Date: 2007-08-09

Last Posted Date: 2014-01-10

Lead Sponsor: Raghu Nandan, M.D., Inc

Target Recruit Count: 39

Registration Number: NCT00514293

Locations: 🇺🇸
R. Nandan M.D. Incorporated, Lakewood, California, United States

Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Leukemia
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases

Interventions: Biological: sargramostim
Drug: bexarotene
Genetic: cytogenetic analysis
Genetic: fluorescence in situ hybridization
Other: flow cytometry
Other: laboratory biomarker analysis
Procedure: biopsy

First Posted Date: 2007-01-23

Last Posted Date: 2018-10-05

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 26

Registration Number: NCT00425477

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Bexarotene
Drug: Erlotinib

First Posted Date: 2006-12-14

Last Posted Date: 2020-01-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 37

Registration Number: NCT00411632

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Study of Bexarotene in Patients With Acute Myeloid Leukemia

Phase 1

Completed

Conditions: AML
Acute Myeloid Leukemia

First Posted Date: 2006-04-19

Last Posted Date: 2016-06-08

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 54

Registration Number: NCT00316030

Locations: 🇺🇸
Abramson Cancer Center of University of Pennsylvania, Philadelphia, Pennsylvania, United States

Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma

Phase 1

Completed

Conditions: Cutaneous T-Cell Lymphoma

First Posted Date: 2006-03-27

Last Posted Date: 2006-03-27

Lead Sponsor: Boston University

Target Recruit Count: 18

Registration Number: NCT00306969

Locations: 🇺🇸
Boston University Medical Center, Boston, Massachusetts, United States

A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

First Posted Date: 2005-10-13

Last Posted Date: 2010-07-20

Lead Sponsor: Stanford University

Target Recruit Count: 12

Registration Number: NCT00238628

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy